BioCryst to Acquire Astria Therapeutics in $700M Deal to Boost Rare Disease Portfolio
BioCryst Pharmaceuticals announces $700M acquisition of Astria Therapeutics, adding promising hereditary angioedema drug to expand rare disease treatment options.
/ 1 item
#BCRX↓